The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
Recent advances in non-small cell lung cancer targeted therapy; an update review
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
Recent progress in targeted therapy for non-small cell lung cancer
Y Xiao, P Liu, J Wei, X Zhang, J Guo… - Frontiers in Pharmacology, 2023 - frontiersin.org
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …
major threats to people's health. With the identification of carcinogenic drivers in non-small …
[HTML][HTML] The emerging treatment landscape of advanced non-small cell lung cancer
P Economopoulou, G Mountzios - Annals of Translational Medicine, 2018 - ncbi.nlm.nih.gov
Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …
advances in diagnostics and therapy, the five-year overall survival for patients with …
Biomarker-targeted therapies in non–small cell lung cancer: current status and perspectives
H Guo, J Zhang, C Qin, H Yan, T Liu, H Hu, S Tang… - Cells, 2022 - mdpi.com
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Y Cheng, T Zhang, Q Xu - MedComm, 2021 - Wiley Online Library
Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …
decades, despite the rapid development of targeted therapy and immunotherapy in non …
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
U Majeed, R Manochakian, Y Zhao, Y Lou - Journal of hematology & …, 2021 - Springer
Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …
Emerging targeted therapies for the treatment of non-small cell lung cancer
PR Halliday, CM Blakely, TG Bivona - Current oncology reports, 2019 - Springer
Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …
[HTML][HTML] Targeted therapies for advanced non-small cell lung cancer
Lung cancer is a serious health problem and the leading cause of cancer death worldwide,
due to its high incidence and mortality. 85% of lung cancers are represented by the non …
due to its high incidence and mortality. 85% of lung cancers are represented by the non …
Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
Lung cancer has the highest incidence of morbidity and mortality throughout the globe. A
large number of patients are diagnosed with lung cancer at the later stages of the disease …
large number of patients are diagnosed with lung cancer at the later stages of the disease …